Trial Progress Buzz: Recent discussions on social media about SELLAS Life Sciences Group have centered on the latest updates to their Phase 3 REGAL trial for acute myeloid leukemia. Many are highlighting the trial’s progress, noting that it’s nearing the final data readout, which could be a major catalyst. There’s a palpable excitement about potential positive outcomes.
Stock Volatility Debate: Conversations also reflect on the stock’s recent volatility, with some pointing to a sharp rebound after a selloff linked to dilution concerns. Others are optimistic, suggesting that successful trial results could drive significant gains. The mix of hope and caution keeps the dialogue dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
SELLAS Life Sciences Group Insider Trading Activity
SELLAS Life Sciences Group insiders have traded $SLS stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SLS stock by insiders over the last 6 months:
- KATHERINE BACH KALIN purchased 63,400 shares for an estimated $100,806
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SELLAS Life Sciences Group Hedge Fund Activity
We have seen 53 institutional investors add shares of SELLAS Life Sciences Group stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANSON FUNDS MANAGEMENT LP added 5,757,938 shares (+2093.8%) to their portfolio in Q3 2025, for an estimated $9,270,280
- BLACKROCK, INC. added 1,096,613 shares (+23.9%) to their portfolio in Q3 2025, for an estimated $1,765,546
- MILLENNIUM MANAGEMENT LLC removed 812,523 shares (-72.1%) from their portfolio in Q3 2025, for an estimated $1,308,162
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 626,097 shares (-42.0%) from their portfolio in Q3 2025, for an estimated $1,008,016
- DAGCO, INC. added 577,540 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,177,325
- GOLDMAN SACHS GROUP INC removed 446,241 shares (-95.9%) from their portfolio in Q3 2025, for an estimated $718,448
- MARSHALL WACE, LLP removed 357,490 shares (-13.2%) from their portfolio in Q3 2025, for an estimated $575,558
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
